Correlation between Vitamin D Receptor SNP ApaI and liver fibrosis in HCV patients from Thrace

Similar documents
Relationship between antibodies to hepatitis C virus core+1 protein and treatment outcome

Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

HEPATITIS C UPDATES. Sanaa S. Said 10 th April, 2014

UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA DOCTORAL SCHOOL DOCTORAL THESIS

Hepatitis C in Australia:

Hepatitis C Management and Treatment

Hepatitis. Dr. Mohamed. A. Mahdi 5/2/2019. Mob:

Hepatitis C. Core slides

Treatment of a patient with genotype 7 HCV infection with sofosbuvir and velpatasvir. Moreno 1

ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT

Hepatitis C in Disclosures

HCV eradication with direct acting antivirals (DAAs)? Why is viral cure possible in HCV? Emilie Estrabaud

ASSESSMENT PRIOR TO TREATMENT DO WE NEED IL28B TESTING?

Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial

Screening for HCCwho,

Clinical Immunology & Research

Vicente Soriano Department of Infectious Diseases

RESEARCH ARTICLE. Rattanaporn Kiatbumrung 1, Natthaya Chuaypen 1, Sunchai Payungporn 1, Anchalee Avihingsanon 2, Pisit Tangkijvanich 1 * Abstract

Dr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust

The Egyptian Journal of Hospital Medicine (October 2018) Vol. 73 (10), Page

29th Viral Hepatitis Prevention Board Meeting

Hepatitis C wi w t i h Ju J dy y W y W a y t a t t

The Changing World of Hepatitis C

Hepatitis C Virus.

EPIDEMIOLOGY, CLINICAL FEATURES AND OUTCOME OF ACUTE HEPATITIS C IN HIV-POSITIVE PATIENTS: PRESENTATION OF OUR EXPERIENCE

Hepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain

Treatment of chronic hepatitis B 2013 update

Viral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital

Dr Kate Childs. King s College Hospital NHS Foundation Trust, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014

NIH Consensus Conference Statement. Management of Hepatitis C. March 24-26, NIH Web site. Available at:

THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE

Hepatitis C Update. Geri Brown, M.D. Associate Professor Department of Internal Medicine March 24, 2011

Genotype 4. Sanaa Kamal, M.D., Ph.D. Professor. Ain Shams University, Cairo, Egypt Tufts School of Medicine

Clinical dilemmas in HBeAg-negative CHB

Persistent Infections

Genetic Determinants in HCV

Delta hepatitis: How to manage and optimize therapy? Dominique ROULOT Unité d Hépatologie, Hôpital Avicenne

Disclosures 29/09/2014. Genetic determinants of. HCV treatment outcome. IDEAL: IL28B-type is the strongest pre-treatment predictor of SVR

Antiviral agents in HCV

Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician

Supplementary Table 1. The distribution of IFNL rs and rs and Hardy-Weinberg equilibrium Genotype Observed Expected X 2 P-value* CHC

«Εκτίμηση κινδφνου ανάπτυξης ΗΚΚ σε ασθενείς με HCV λοίμωξη» Evaluation of HCC risk in HCV patients

Bioinformation by Biomedical Informatics Publishing Group

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

National Clinical Guidelines for the treatment of HCV in adults. Version 5

Some HCV History 1970s: many cases reported called non-a, non-b hepatitis

HEPATITIS C VIRUS (HCV) GENOTYPE TESTING

MedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article

RECOMMENDATION FOR THE MANAGEMENT OF HEPATITIS C VIRUS INFECTION AMONG PEOPLE WHO INJECT DRUGS

Scottish Medicines Consortium

Should Elderly CHC Patients (>70 years old) be Treated?

Epatite Cronica C Definizione dei Prototipi Clinici per la Personalizzazione Terapeutica Genotipo 4. Gloria Taliani Sapienza Università di Roma

PEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced

Update in hepatitis C virus infection

Treatment of chronic hepatitis C in HIV co-infected patients

Viral and Host Factors in Vulvar Disease DR MICHELLE ETHERSON 26 TH OF APRIL 2016

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

Antiviral Therapy 2012; 17: (doi: /IMP2018)

QUANTITATIVE HEPATITIS C VIRUS (HCV) RNA

Who to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat

Hepatitis C Virus SARS-Co Virus. Neerja Kaushik-Basu Biochemistry and Molecular Biology Oct

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Treatment strategies for recurrent hepatitis C after living donor liver transplantation (from Kyushu University experience)

HEPATITIS C TREATMENT GUIDANCE

Pre-Assessment Review: Microbiology, Part 2: Virology. Dr. David Hillyard

New York State HCV Provider Webinar Series. Side Effects of Therapy

CDC website:

ROLE OF IL28B AND ITPA POLYMORPHISMS IN DIFFERENT GENOTYPES OF HCV

Section 3: Testing and Diagnosis of Hepatitis C

Updates in the Treatment of Hepatitis C

Nucleic acid Strands Family Example Accession Base pairs

National Clinical Guidelines for the treatment of HCV in adults. Version 4

How to optimize treatment for HCV Genotype 4

SYNOPSIS Final Clinical Study Report for Study AI444031

Assessing the patient with a new diagnosis of Hepatitis C LAUREN MYERS MMSC, PA-C OREGON HEALTH & SCIENCE UNIVERSITY

Population Viral Kinetic Modeling: SVR Prediction in HCV GT-3 Cirrhotic Patients With 24 Weeks of Daclatasvir + Sofosbuvir Administration

PROPOSAL FOR THE DEVELOPMENT OF AN INTERNATIONAL REFERENCE PREPARATION FOR HEPATITIS D VIRUS RNA

Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics

Treatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain

Module 1 Introduction of hepatitis

Current Treatments for HCV

EPIDEMIOLOGICAL HETEROGENEITY OF INFECTIONS WITH HEPATITIS B AND D VIRUSES IN BRAZIL

Hepatitis C SYMPTOMS COMPLICATIONS

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

2. Liver blood tests and what they mean p2 Acute and chronic liver screen

Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov

Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

General Statement for Drugs for the Treatment of Hepatitis C

Phase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:

9/29/2014. Patterns of hepatitis C virus RNA levels during acute infection: the InC 3 study. Background. Background. Background

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

VIRAL AND AUTOIMMUNE HEPATITIS WHAT IS HEPATITIS?

Analysis of Hepatitis C Virus using Data mining algorithm -Apriori, Decision tree

Treatment Options in HCV Relapsers and Nonresponders. Raymond T. Chung, M.D.

Clinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Transcription:

Correlation between Vitamin D Receptor SNP ApaI and liver fibrosis in HCV patients from Thrace A. Beka 1, T. Mylopoulou 2, V. Papadopoulos 2, I. Karakasiliotis 2, P. Mavromara 1, K. Mimidis 2, S. Veletza 2 1 DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS, DEMOCRITUS UNIVERSITY OF THRACE, ALEXANDROUPOLIS, GREECE 2 DEPARTMENT OF MEDICINE, DEMOCRITUS UNIVERSITY OF THRACE, ALEXANDROUPOLIS, GREECE

HCV infection is a major public health problem 71 million with chronic HCV infection worldwide (1% of the population.) 1.75 million new infections in 2015 ~399.000 deceased yearly 15-45% spontaneous clearance There is no vaccine available Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY- NC-SA 3.0 IGO

Pathogenesis of HCV infection Normal Chronic Liver Liver Hepatocellular Liver Infection Steatosis Cirrhosis Carcinoma Ke and Chen (2012) Hepatitis C Virus and Cellular Stress Response: Implications to Molecular Pathogenesis of Liver Diseases. Viruses (doi: 10.3390/v4102251), edited

Hepatitis C virus Member of the Flaviviridae family - Hepacivirus genus Positive-sense single stranded RNA Blausen Medical Communications Abdel-Hakeem MS and Shoukry NH (2014) Protective immunity against hepatitis C: many shades of gray. Front. Immunol. 5:274. doi: 10.3389/fimmu.2014.00274

HCV has an increased genetic heterogeneity 1 6 5 4 HCV genotype influences the outcome of PEG- IFN/RBV therapy and viral pathogenicity. 7 3 2 Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T. and Simmonds, P. (2014), Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology, 59: 318 327. doi:10.1002/hep.26744

The role of host genetic heterogeneity in HCV infection IFNL3 C/C IFNL4 T/T HCV-1,2,3 and 4Higher RVR rates MTTP TT or TG HCV-3 Higher levels of liver steatosis VDR bat haplotype CCA and ApaI CC HCV-1/2/3 Swiss patients Rapid fibrosis Riva et al, review, Clinical Microbiology and Infection, 2014, Zampino et al, Journal of Viral Hepatitis, 2008, Baur et al, Liver International, 2012

Why VDR? Low 25(OH) D levels are correlated to advanced fibrosis. VDR polymorphisms have been associated with rapid fibrosis progression in HCV patients from Switzerland and Brazil Petta et al, 2010, Baur et al, 2012, Paula Scalioni et al 2018, Gascon-Barre et al, 2003

Aim To investigate the possible association of VDR ApaI (rs7975232) genotype of HCV monoinfected patients from Thrace-Greece with the stage of liver fibrosis.

Experimental design HCV RNA positive FibroScan Collecting blood samples DNA isolation PCR ApaI Digestion Gel Electrophoresis Patient characteristics n = 67 Gender (Male/Female) 46/21 Age Average 52 (22-78) Ethnicity Caucasian (100%) HCV genotype 1 36 HCV genotype 3 22 HCV non1-non3-genotype 9 FibroScan 0-1 25 FibroScan 2 10 FibroScan 3 8 FibroScan 4 / Cirrhotic 24 FibroScan Interpretation F0-1 2-6.9 kpa F2 7-9 kpa F3 10-14 kpa F4 14-75 kpa

Experimental design HCV RNA positive FibroScan Collecting blood samples DNA isolation PCR ApaI Digestion Gel Electrophoresis Credit: Genome Decoration Page /NCBI CAGAGCATGGACAGGGAGCAAGGCCAGGCAGGGACAGGGCCAGGTGCGCCCATGGAAGGACCTAGGTC TGGATCCTAAATGCACGGAGAAGTCACTGGAGGGCTTTGGGGCCAGGCAGTGGTATCACCGGTCAGCAGTCATAGA GGGGTGGCCTAGGGGGTGCTGCCGTTGAGTGTCTGTGTGGGTGGGGGGTGGTGGGATTGAGCAGTGAGGGGC CCAGCTGAGAGCTCCTGTGCCTTCTTCTCTATCCCCGTGCCCACAGATCGTCCTGGGGTGCAGGACGCCGCGCTGAT CGAGGCCATCCAGGACCGCCTGTCCAACACACTGCAGACGTACATCCGCTGCCGCCACCCGCCCCCGGGCAGCCAC CTGCTCTATGCCAAGATGATCCAGAAGCTAGCCGACCTGCGCAGCCTCAATGAGGAGCACTCCAAGCAGTACCGCTG CCTCTCCTTCCAGCCTGAGTGCAGCATGAAGCTAACGCCCCTTGTGCTCGAAGTGTTTGGCAATGAGATCTCCTGACT AGGACAGCCTGTGGCGGTGCCTGGGTGGGGCTGCTCCTCCAGGGCCACGTGCCAGGCCCGGGGCTGGCGGCTAC TCAGCAGCCCTCCTCACCCCGTCTGGGGTTCAGCCCCTCCTCTGCCACCTCCCCTATCCACCCAGCCCATTCTCTCTCC TGTCCAACCTAACCCCTT ApaI SNP

Results Ld 1 2 3 4 5 6 7 8 9 10 11 12 N PCR product 695bp Ld 1 2 3 4 5 6 7 8 Ld ApaI Digestion Possible Outcomes: T 695bp G 482bp 213bp

Results 100% 90% VDR ApaI genotype GG is linked to low fibrosis 80% 70% 60% 50% 40% 30% 20% high fibrosis (n=32) low fibrosis (n=35) 10% 0% TT GG TG P = 0.032

Results 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% F4 (n=24) F0-1 (n=25) VDR ApaI TT and TG genotypes that are linked to advanced fibrosis and cirrhosis 0% TT GG TG P=0.006 P=0.016 P=0.006

Conclusion VDR ApaI genotype GG is linked to low fibrosis progression, in contrast to the TT and TG genotypes that are linked to advanced fibrosis and cirrhosis.

Acknowledgements Biochemistry and Molecular Virology Molecular Biology and Genetics P. Mavromara K. Katsani M. Cheilas E. Filippopoulou Medical Biology Department of Medicine S. Veletza I. Karakasiliotis E. Gatzidou T. Georgoudis Internal Medicine General University Hospital K. Mimidis T. Mylopoulou

Thank you for your attention!!!